Zentalis Pharmaceuticals Q3 net loss narrows

Zentalis Pharmaceuticals

10/11/2025 21:17

Overview

Zentalis Q3 operating expenses decreased to $33.7 mln from $51.4 mln last year

Net loss for Q3 2025 was $26.7 mln, an improvement from $40.2 mln last year

Company has $280.7 mln in cash, supporting operations into late 2027

Outlook

Company's cash supports operations into late 2027

Result Drivers

COST REDUCTION - Decrease in R&D expenses contributed to lower operating expenses for the quarter

STRONG CASH POSITION - Company has $280.7 mln in cash, supporting operations into late 2027

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.37
Q3 Net Income
-$26.69 mln
Q3 Operating Expenses
$33.73 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Zentalis Pharmaceuticals Inc is $5.50, about 76.7% above its November 7 closing price of $1.28

Press Release: ID:nGNX24RF7F

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)